2014
DOI: 10.7150/jca.7709
|View full text |Cite
|
Sign up to set email alerts
|

Current Approaches, Challenges and Future Directions for Monitoring Treatment Response in Prostate Cancer

Abstract: Prostate cancer is the most commonly diagnosed non-cutaneous neoplasm in men in the United States and the second leading cause of cancer mortality. One in 7 men will be diagnosed with prostate cancer during their lifetime. As a result, monitoring treatment response is of vital importance. The cornerstone of current approaches in monitoring treatment response remains the prostate-specific antigen (PSA). However, with the limitations of PSA come challenges in our ability to monitor treatment success. Defining PS… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
65
0
1

Year Published

2015
2015
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 80 publications
(68 citation statements)
references
References 153 publications
(158 reference statements)
2
65
0
1
Order By: Relevance
“…19,21 The ability to distinguish local recurrence from systemic disease with posttreatment imaging may be critical because local recurrence is often amenable to local salvage treatment. 22 Some criteria, such as time to biochemical failure, PSA doubling time and positive surgical margins, were proposed to differentiate local recurrence from systemic disease. 23 However, imaging may still be needed to detect disease relapse in the absence of increased PSA 24 or in cases in which increased PSA after RP is suspected to be due to retained benign tissue.…”
Section: Discussionmentioning
confidence: 99%
“…19,21 The ability to distinguish local recurrence from systemic disease with posttreatment imaging may be critical because local recurrence is often amenable to local salvage treatment. 22 Some criteria, such as time to biochemical failure, PSA doubling time and positive surgical margins, were proposed to differentiate local recurrence from systemic disease. 23 However, imaging may still be needed to detect disease relapse in the absence of increased PSA 24 or in cases in which increased PSA after RP is suspected to be due to retained benign tissue.…”
Section: Discussionmentioning
confidence: 99%
“…The medical profession mentions the increasing epidemic of skin cancer but the unique nature of the visibility and accessibility of the skin allows easy and rapid assessment of potentially malignant lesions [11,12]. The only tools required are clinical acumen and a through knowledgeable approach.…”
Section: Methodsmentioning
confidence: 99%
“…Yüksek riskli grup; evre T3a veya Gleason skoru 8-10 veya PSA >20 ve çok yüksek riskli grup ; T3b ve T4 hastalık olarak tanımlanmıştır. Tedavi kararı hastanın tanı anındaki risk grubuna, öngörülen yaşam süresine, hastanın kendi tercihlerine bağlıdır (5). Lokalize prostat kanserinde hatta düşük riskli hastalıkta başlıca tedavi yöntemi radikal prostatektomidir.…”
Section: Introductionunclassified